営業利益率
2018年以降
計算
Moderna Inc.、営業利益率、長期トレンド計算
| 営業利益率 | = | 100 | × | 営業利益(損失)1 | ÷ | 製品販売1 | |
|---|---|---|---|---|---|---|---|
| 2023/12/31 | -63.54% | = | 100 | × | (4,239) | ÷ | 6,671) |
| 2022/12/31 | 51.10% | = | 100 | × | 9,420) | ÷ | 18,435) |
| 2021/12/31 | 75.22% | = | 100 | × | 13,296) | ÷ | 17,675) |
| 2020/12/31 | -381.82% | = | 100 | × | (763) | ÷ | 200) |
| 2019/12/31 | — | = | 100 | × | (546) | ÷ | —) |
| 2018/12/31 | — | = | 100 | × | (413) | ÷ | —) |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31).
1 百万米ドル
競合他社との比較
Moderna Inc.、営業利益率、長期トレンド、競合他社との比較
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| 2023/12/31 | -63.54% | 23.49% | 29.35% | 21.77% | 28.24% | 30.85% | 16.00% | 38.83% |
| 2022/12/31 | 51.10% | 31.21% | 38.57% | 27.61% | 27.17% | 38.93% | 18.69% | 48.23% |
| 2021/12/31 | 75.22% | 31.89% | 31.44% | 25.35% | 36.72% | 55.67% | 25.57% | 36.73% |
| 2020/12/31 | -381.82% | 24.81% | 37.70% | 18.99% | 16.72% | 42.09% | 24.19% | 46.03% |
| 2019/12/31 | — | 39.03% | 43.57% | 18.25% | 19.38% | 28.10% | 17.99% | 28.77% |
| 2018/12/31 | — | 19.49% | 45.55% | 17.11% | 37.83% | 37.77% | 15.53% | 20.84% |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31).